So far, so good” was at least one reaction – though not the market’s – to phase I data uncorked by Macrogenics Inc. at the European Society for Medical Oncology meeting in Madrid, where attendees ...

Gilead Sciences Inc. is paying $1.28 billion in cash to acquire Pepstar Therapeutics Ltd.’s oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, to deepen its presence in immunology ...

The 2026 European Society of Medical Oncology (ESMO) 2026 annual meeting kicked off with a bit of drama, as Merck & Co. Inc. and Moderna Inc. released the full data from their Interpath-001 study two ...

Researchers from the University of Osaka have found that, long before antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis progresses to overt kidney injury, stressed renal ...

Japan has backed Nipro Corp.’s Stemirac for full approval, about eight years after the mesenchymal stem cell therapy first ...

Researchers at ETH Zürich have developed an implant that catalyzed the oxidation of glucose to gluconate, a metabolite that is easily excreted by the kidneys. In mice, the device could rapidly bring ...

Phase III news from competitor Abbvie Inc. in hidradenitis suppurativa (HS) put a sizeable dent in shares of Avalo ...

The next breakthrough in artificial intelligence-driven drug discovery may depend less on more sophisticated algorithms than ...

Ryvu Therapeutics SA recently presented data for RVU-602, a proprietary non-TOPO1/non-tubulin antibody-drug conjugate (ADC) ...

Worldwide biopharma approvals reached 57 in September, up 50% from August’s 38 and coming in as the second-highest monthly total of the year, behind June’s 64. Through the first three quarters of 2026 ...

Fractyl Health Inc. is determined to pursue the development of its Revita system despite its battered share price and looming litigation. It is cutting nearly half of its workforce, discontinuing the ...

Arbor Biotechnologies Inc. has nominated three CNS-focused gene editing development candidates: ABO-201 for familial ...